Objectives: Osteopontin (OPN) is an extracellular matrix protein with diverse immunomodulatory functions. We assessed safety, tolerability, pharmacokinetics, pharmacodynamics and initial efficacy of the humanised monoclonal antibody ASK8007, which blocks OPN.
Despite marked improvement in treatment of rheumatoid arthritis (RA) over the last decade, there is still a need for new and better treatments, as not all patients respond.
1 This unmet need requires further exploration of therapeutic options by identifying new possible targets.
One such target is the extracellular matrix glycoprotein osteopontin (OPN). It is constitutively expressed in bone and epithelial tissues under physiological conditions, but inflammatory stimuli upregulate the production by activated T cells, macrophages, chrondrocytes and synoviocytes. 2 OPN, meaning 'bone-bridging' protein, is thought to act like a bridge between bone matrix and osteoclasts, which are important in both joint inflammation and destruction. 3 The arginine-glycine-aspartate sequence (RGD) motif of full-length OPN protein interacts with αvβ3 and αvβ5 integrins expressed on osteoclasts, monocytes, lymphocytes and neutrophils, and with cell surface receptor CD44 and is important in immunomodulation, cell adhesion, chemotaxis and activation of osteoclasts. [4] [5] [6] After cleavage of OPN by thrombin, the cryptic binding site SVVYGLR is exposed, which also promotes cell adhesion and migration by interacting with α9β1 and α4β1 integrins, but in an RGD-independent manner. 7 Cumulative evidence suggests an important role for OPN in the pathogenesis of RA. OPN-deficient mice were protected from joint destruction in anti-type II collagen antibodyinduced arthritis and showed significantly reduced arthritic scores compared with wild-type mice. 8 In RA patients, higher OPN levels could be detected in synovial fluid (SF) compared with serum from the same patients or control sera. 9 In addition, the ratio of the cleaved versus non-cleaved form was increased in RA SF, suggesting an important role for the cleaved form as well. 10 OPN expression is also increased in RA synovial tissue (ST) compared with osteoarthritis. 11 Although thought of as being a T helper cell (Th)1 cytokine, 12;13 evidence for a role of OPN in Th17 differentiation in rheumatoid synovitis as well has recently been published. 14 ASK8007 is a humanised, monoclonal IgG1 antibody directed against the human cryptic epitope SVVYGLR that inhibits both RGD-and α9β1 integrin-dependent cell binding to human OPN. 15 For a proof-of-concept study in experimental arthritis, the rabbit anti-mouse antibody M5, recognising the thrombin cleavage sequence in mouse and rat OPN, was designed. 7 In vitro, M5 inhibited monocyte migration towards thrombin-cleaved OPN and also interleukin (IL)-1-and parathyroid hormone-stimulated bone resorption. 16 Furthermore, treatment with M5 inhibited joint inflammation and destruction in both antibody-induced and collageninduced arthritis (CIA) in mice. 16 OPN blockade with the antibody C2K1-a chimeric antibody similar to ASK8007, which cross-reacts with monkey OPN-was also effective in a monkey CIA model with favourable toxicology results. 17 The aim of the present study was to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and initial proof of efficacy of ASK8007 in the treatment of RA.
PATIENTS AND METHODS
Patient selection. Adult patients with active polyarthritis were included in a two-part study. All patients fulfilled the 1987 American College of Rheumatology (ACR) classification criteria for RA. 18 In Part A, active disease was defined as a disease activity score evaluated in 28 joints (DAS28) >4.5. For Part B, patients had to have ³6 swollen joints out of 66 (one of which was a knee or ankle joint to allow arthroscopy), ³6 tender joints out of 68 and fulfil at least one of the following criteria: C-reactive protein (CRP) levels ≥1.5 mg/dL, erythrocyte sedimentation rate (ESR) ≥28 mm/hr or morning stiffness ≥45 minutes. Patients were being treated with an adequate dose (to the discretion of the local physician) of either methotrexate (MTx) or leflunomide (Part A) or either MTx, leflunomide or sulfasalazine (Part B) for ≥4 months prior to baseline of which the last 6 weeks at a stable dose. Use of any other disease-modifying antirheumatic drugs (DMARDs), including etanercept, was discontinued ≥1 month prior to initiation of treatment. For infliximab, a wash-out period of 3 months was defined, for adalimumab this was 2 months. Previous use of rituximab was not allowed. Oral corticosteroids (£10 mg/day) and non-steroidal anti-inflammatory drugs (NSAIDs) were allowed, provided the dose had not been changed within 4 weeks before baseline. Several other in-and exclusion criteria applied. The study was approved by the Medical Ethics Committee of the participating centres and performed according to the Declaration of Helsinki. All participants gave written informed consent.
Study design. This was a randomised, double-blind, placebo-controlled, combined first-inman, dose-escalation study (Phase I, Part A) and proof-of-concept, multiple-dose study (Phase IIA, Part B) performed at nine study centres (in Hungary, the United Kingdom, Spain, Ireland, Belgium and the Netherlands). In Part A, patients were treated with a single dose of 0.3, 1.25, 5 or 20 mg/kg ASK8007 or matching placebo administered intravenously over 2 hours in four consecutive dose cohorts of eight patients each with a follow-up for 16 weeks after dosing. Within each cohort, randomisation allocated six subjects to treatment with ASK8007 and two subjects to placebo. Escalation to the next higher dose cohort was only allowed after review by a safety committee of ≥2 weeks safety data from all eight patients of the previous cohort.
In Part B, newly recruited patients received three consecutive infusions (over 2 hours each) of 20 mg/kg ASK8007 or placebo on Day 1, 8 and 29 and were followed for 10 weeks after the last infusion. Randomisation in a 2:1 ratio allocated 36 subjects to treatment with ASK8007 and 18 subjects to placebo. The two co-primary efficacy endpoints were the change from baseline in DAS28-ESR and the change from baseline in the number of CD68 + sublining macrophages in synovium, both assessed on Day 43 in Part B.
Clinical assessment, safety, pharmacokinetics and pharmacodynamics. Routine safety and clinical assessments and lab tests were performed frequently throughout both parts of the study. Patients were evaluated clinically according to DAS28-ESR, 19 European League Against Rheumatism (EULAR) response criteria 20 and ACR response criteria. 21 Blood was collected before dosing and post-dose at 0.25, 1, 2, 3, 5, 8 hours and less frequently thereafter for extensive pharmacokinetic analysis in plasma (Part A only). ASK8007 and OPN concentrations were also measured in SF (Part B only, collected on Day 0 and 43) and urine. The ELISA for analysis of full-length OPN did not distinguish between free and complexed OPN. Biomarkers of inflammation and of cartilage and bone destruction were measured in serum, SF, ST and urine (see Supplementary Table) .
Collection of synovial tissue and synovial fluid, and immunohistochemical analysis. In Part B, a needle arthroscopy was performed at baseline and at Day 43 to obtain ST samples and SF from an actively inflamed knee or ankle, as previously described. 22 ( KAKETSUKEN, Kumamoto, Japan) and subsequently a three-step immunoperoxidase method with aminoethylcarbazole (AEC; Dako, Glostrup, Denmark) as dye, as previously described. 24 Next, sections were blindly and randomly analysed, and quantified using digital image analysis, as previously described. 24;25 Statistical analysis. An analysis set for safety data, demographic and all baseline characteristics was defined for subjects, who had received ≥1 dose of the study drug (Safety Analysis Set [SAF]). The primary set for analysis of efficacy variables and biomarkers (Full Analysis Set [FAS]) was defined as those randomised subjects, who had received ≥1 dose of the study drug and had complied with ≥1 post-baseline efficacy/pharmacodynamic assessment. For Part B, a secondary analysis set for efficacy variables and biomarkers (Per Protocol Set) was defined as a subset of the FAS for subjects, who had adhered to the protocol.
Changes in DAS28-ESR and CD68 + synovial sublining cells from baseline to Day 43 in Part B-with Last Observation Carried Forward for missing data for DAS28-ESR-were compared between treatment groups using the analysis of covariance (ANCOVA) model with treatment as the main effect and baseline as the covariate. Changes from baseline in the number of CD68 + sublining cells in paired ST samples were also analysed using an ANCOVA model. ACR and EULAR response rates were compared using the Fisher's exact test. Other variables, e.g., patient baseline characteristics, adverse events (AEs) and biomarkers, were not statistically tested for differences in order to prevent multiple testing. All statistical analyses were performed with SAS software (v9.1, SAS Institute, Cary, NC, USA). A P-value of ≤0.05 was considered statistically significant.
RESULTS
Patient disposition and baseline characteristics. In Part A, 32 patients were randomised into the four dose groups, each of which included matching placebo. All patients completed the assessments. In Part B, 73 patients were screened; 54 patients were randomised and received ≥1 dose of either 20 mg/kg ASK8007 (n = 36) or placebo (n = 18). The majority of the patients completed the study (43 patients, 80%; Figure 1 ). In general, treatment groups were similar with respect to baseline characteristics in both parts of the study, although patients in the placebo group of Part B seemed to have a longer median disease duration of RA than subjects randomised to ASK8007 (Table 1) .
Pharmacokinetic findings. The mean (SD) half-life of ASK8007 ranged from 286 (141) to 351 (77) hours and was independent of dose. Quantifiable concentrations of ASK8007 were detected in SF of actively treated patients (for those of whom SF was available for analysis), indicating that ASK8007 reaches the site of inflammation (data not shown). For additional information, see Supplementary File.
Effect of ASK8007 on osteopontin concentrations in different compartments. Administration of ASK8007 led to an increase in full-length OPN levels in plasma, which was most apparent in the 20 mg/kg treatment group (Figure 2) . No quantifiable plasma concentrations were obtained for (N-terminal) cleaved OPN at baseline or after treatment. Changes in plasma OPN concentrations were not reflected in urine.
Baseline ST OPN expression was highly variable between patients. After ASK8007 administration, a trend towards an increase in OPN expression was observed without a clear difference between ASK8007-and placebo-treated patients. For full-length and cleaved OPN in SF, no conclusions could be drawn due to the limited number of samples.
Treatment with ASK8007 is well tolerated. In Part A, administration of ASK8007 was well tolerated up to the highest studied dose of 20 mg/kg. None of the patients discontinued from the study due to AEs. One non-related serious AE (SAE) was observed: a 46-year-old, female patient experienced an acute myocardial infarction starting 73 days after infusion of a single dose of 5 mg/kg ASK8007, which was treated with the placement of a stent.
In Part B, overall, 15 (42%) patients in the ASK8007 group experienced AEs compared with 10 (56%) placebo-treated patients. The most commonly reported AE was nausea; events experienced by ≥2 patients are listed in Table 2 . One SAE was observed: a 65-year-old, female patient had severe angina pectoris starting 12 days after the second infusion with ASK8007 (Day 20 of the study), which resulted in her death. The event was considered possibly related to treatment by the investigator and cause of death was reported as myocardial infarction (no autopsy was performed). Additional information revealed that the subject had multiple risk factors for cardiovascular events in addition to RA, including smoking, hypertension for which she received medical treatment, NSAID use and elevated blood cholesterol levels. None of the other subjects discontinued from the study due to AEs. ; all had to remain on background treatment with one non-biological DMARD; those on methotrexate (i.e., 83%) had received a mean dose of 16 mg/week. BMI = body mass index; RF = rheumatoid factor; anti-CCP = anti-cyclic citrullinated peptide antibodies; ACR = American College of Rheumatology; DAS28-ESR = disease activity score of 28 joints based on erythrocyte sedimentation rate; DMARD = disease-modifying antirheumatic drug.
Treatment with ASK8007 does not result in clinical improvement. The first primary endpoint, the change from baseline in DAS28 as assessed on Day 43, was not different between ASK8007-treated (n = 33) and placebo-treated (n = 16) patients (P = 0.95; Table 3A ). In addition, no significant difference was observed in the second primary endpoint, the change in CD68 + sublining macrophages, between ASK8007-(n = 9) and placebo-treated (n = 4) patients (P = 0.61; Table 3B ). Paired analysis did not show a clear-cut decrease in sublining macrophages within the ASK8007 treatment group either (P = 0.86). Throughout the study, the mean DAS28 did not differ between the two treatment groups at any study visit (Figure 3) . The number and percentage of subjects meeting the criteria for the ACR20/50/70 at each visit was low, with no relevant difference between ASK8007 and placebo. Consistently, there was no relevant difference with respect to the number and percentages of subjects with good, moderate or no response according to the EULAR response criteria using ESR and CRP (data not shown). Mean (SD) disease activity score of 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) at baseline and Day 43 (Part B) from rheumatoid arthritis patients treated with 20 mg/kg ASK8007 or placebo are shown; these data were part of the Full Analysis Set. The mean change (∆DAS28-ESR) was compared using the ANCOVA model. Analysis using the Per Protocol Set showed similar results.
No effect of ASK8007 treatment on biomarkers of inflammation or joint destruction. Neither single nor multiple (20 mg/kg) doses ASK8007 administered over a 4-week period had an effect on the levels of any of the biomarkers tested (listed in Supplementary Table) . Moreover, all results were within the inherent variability of each biomarker and no ASK8007-related trends or signs of a change different from that observed in the placebo group were seen (data not shown).
DISCUSSION
In this randomised, placebo-controlled, double-blind, combined Phase I, first-in-man, doseescalation study and Phase IIA, proof-of-concept, multiple-dose study, we evaluated the effects of treatment with ASK8007, a humanised antibody that blocks OPN, for RA. Overall, ASK8007 administration appeared well tolerated up to a dose of 20 mg/kg by patients with active, moderate to severe RA and was not related to AEs. However, the co-primary efficacy endpoints were not met after treatment with multiple doses of ASK8007. The change from Mean (SD) number of CD68+ synovial sublining cells (cell count/mm2) at baseline and Day 43 (Part B), and the mean (SD) change between these time points. For further details, see legend to Table 3A .
baseline in DAS28-ESR as assessed on Day 43 was not different between the two treatment allocations. Moreover, there was no decrease in synovial sublining macrophages after ASK8007 treatment. ASK8007 also did not affect other biomarkers of inflammation or joint destruction in any of the compartments tested. There are several possible reasons that could explain the observed lack of efficacy. First, the trial design might be a reason. The effect of ASK8007 may have been evaluated too early, the dosing could be suboptimal or the number of patients included too small. The maximum dose of 20 mg/kg used is, however, quite high for monoclonal antibody treatment, and, based on previous studies with such therapies, after 6 weeks of treatment, a clinical response or decrease in synovial sublining macrophages would have been expected. Effective treatment has been consistently associated with a reduction in CD68 + macrophages in the synovial sublining, even before clinical improvement and also in small proof-of-principle studies. 26 Similar to this synovial biomarker, DAS28 has high sensitivity to change in studies with ≤15 patients per arm. 26;27 Second, it is conceivable that ASK8007 did not sufficiently bind to the native form of OPN, since the cell clone was elicited by immunising mice with peptides of OPN. Insufficient binding of ASK8007 to native OPN in RA patients could theoretically be consistent with the efficacy found in the monkey CIA model 17 , which investigated treatment with C2K1 and ASK8007 (ASK8007 is the further humanised version of C2K1) in monkeys with relatively mild arthritis, while patients in the present study had moderate to severe RA. However, insufficient binding of ASK8007 to OPN seems unlikely or can only partly explain lack of efficacy, since a dose-dependent increase of systemic OPN was observed upon ASK8007 administration. This is suggestive of OPN-ASK8007 complex formation and an increase in total ligand levels upon administration of a specific antibody has been observed before. 28 There are two possible explanations for this phenomenon: ASK8007 increases the shedding of OPN from the endothelium by binding to OPN, and/or the dynamic equilibrium of OPN entering and leaving the peripheral blood compartment is disturbed by ASK8007 because of the formation of OPN-ASK8007 complexes that have a slower rate of leaving the intravascular compartment. This results in accumulation of systemic, but only partially bioactive OPN, as only free OPN is able to bind cells and induce its effects. Of note, the increase in total OPN levels in peripheral blood is not of the same order of magnitude as that seen after chemokine ligand CCL2 blockade and it appears unlikely that this increase explains the lack of efficacy observed in the present study. The finding that OPN expression in ST did not decrease after treatment can also be explained by the fact that we stained for both free and complexed OPN. Additionally, ASK8007 was able to reach the synovial compartment, because we observed quantifiable concentrations of ASK8007 in the SF samples available post-treatment.
Finally, our data may indicate that OPN is not a good therapeutic target in RA after all. Chemotaxis is considered to be one of the most important roles of OPN in inflammation. It was recently shown this is mediated through its unique ability of inducing CCL2 expression in CD14 + monocytes, 29 but modulation of CCL2 or its receptor CCR2 have not resulted in amelioration of synovial inflammation in RA. 28;30 Further evidence does not only include lack of clinical improvement and persistent CD68 + macrophage infiltration, but also the absence of any effect on soluble biomarkers associated with bone and cartilage remodelling after ASK8007 treatment. It is generally accepted that the interaction between the RGD region of OPN and αvβ3-integrins expressed by osteoclasts is essential for osteoclastic bone resorption. 6 However, studies with a synthetic SVVYGLR peptide suggested that the OPN epitope revealed after thrombin cleavage and also inhibited by ASK8007, promotes attachment and proliferation of osteogenic cells, and suppresses osteoclastogenesis. 31 Thus, ASK8007 could theoretically even have opposite effects on osteoclastogenesis, which might explain in part why we did not observe a beneficial effect on the soluble biomarker panel for joint destruction. Moreover, in contrast to findings in the collagen antibody-induced arthritis model, 8 arthritis was not reduced in OPN-deficient mice in the K/BxN serum-transfer model compared with their OPN-sufficient littermates. 32 The two SAEs that occurred in two ASK8007-treated patients were probably both myocardial infarctions. The Independent Safety Committee of the study, consisting of senior rheumatologists and a senior cardiologist, did not consider them related to ASK8007 and recommended continuation of the clinical trial. However, since OPN is a pleiotropic protein, we cannot exclude a relationship with the use of ASK8007.
In conclusion, blocking the extracellular matrix protein OPN is well tolerated and not related to safety concerns. The results of this clinical trial consistently show that OPN blockade is unlikely to induce robust clinical improvement in RA patients. and OPN staining). Bound antibody was detected with a polymer-horseradish peroxidase (HRP) anti-mouse IgG (Envision+ System; Dako) for the CD3, CD68, CD22 and CD55 staining. The IL-1α and OPN staining was performed using a three-step immunoperoxidase method, as previously described. 1 Antibody was detected using aminoethylcarbazole (AEC, Dako) as dye. Sections were counterstained with Gill's hematoxylin. Stained sections were analysed blinded for study treatment and time point.
SUPPLEMENTARY PATIENTS AND METHODS

SUPPLEMENTARY RESULTS
Pharmacokinetic findings
After a 2-hour infusion of 0.3 mg/kg ASK8007, the mean (SD) T max ranged from 3 (1) to 10 (8) hours in Part A. This can be explained by the fact that for the first 24 hours a plateau in ASK8007 concentration is observed due to limited distribution into tissues and the long elimination halflife of ASK8007. A dose-proportional increase was observed in the peak concentration (C max ) and the area under the curve (AUC), when the dose was increased up to 5 mg/kg. The next and final dose of 20 mg/kg resulted in more than dose-proportional increases for C max and AUC (Supplementary Figure) .
Upon 
